We are international
Donate
TEXT SIZE   
   back

History is Made with the First Meeting of the Israeli Myeloma Study Group
By Paula Azulai
Chair, AMEN
The community of myeloma experts responded positively to the invitation from AMEN in cooperation with the Israeli Society of Hematologists. Twenty-nine representatives from key clinical and research centers attended and shared with AMEN the excitement of establishing a nationwide working group for multiple myeloma.
08.02.05
Prof. Lugassy, Paula Azulai, Prof. Polliack

On the 29th of July, the first meeting of the Israeli Myeloma Study Group took place at the Sheraton City Tower. The community of myeloma experts responded positively to the invitation from AMEN in cooperation with the Israeli Society of Hematologists. Twenty-nine representatives from key clinical and research centers attended and shared with AMEN the excitement of establishing a nationwide working group for multiple myeloma.

Co-chaired by Prof. Gil Lugassy, head of the Israeli Society of Hematologists, and Prof. Aaron Polliak, AMEN's Medical Advisor, it was the largest forum of its size ever assembled to address the topic of myeloma. It must be considered a milestone in the history of Israeli myeloma research and treatment, and promises to improve clinical care for all myeloma patients in Israel.

Prof. Ben-Yehuda
Chair of the Study Group
Dr. Hardan
Secretary

At the meeting, which was sponsored by Roche Pharmaceuticals, Prof. Dina Ben-Yehuda, head of the Hematology Dept. at Hadassah en Karem, was elected Chair of the Israeli Myeloma Study Group; Dr. Izhar Hardan was elected Secretary; and Dr. Marilius was elected Clinical Research Coordinator.

Many physicians at the meeting registered for the study group dealing with the registry and database as well for the group of the clinical studies.

The four subjects covered were

  1. Registry

  2. Database
    The registry and database were presented by Dr. Marilius from the Zamenhoff Clinic and Mr. Edelist from AMEN

  3. Basic Research
    A group for basic research will be headed by Mr. Ben Zion Katz, a scientist at Ichilov Medical Center. He will organize scientists from Weizman Institute, from universities and other medical research centers dealing with myeloma.

  4. Clinical Studies
    The Clinical Study Program was presented by Dr. Izhar Hardan from Tel Hashomer.

Additional topics for study and research were suggested by Dr. Amos Cohen of the Meir center, Mrs. Dorit Neuman of the University of Tel Aviv, Dr. Gesundheit of the Bone Marrow Transplant Unit at Hadassah en Karen, Dr. Bullvick of Lainiado Hospital, and Prof. Berrebi of Kaplan Medical Center.

AMEN, having made its goal to search for a cure for myeloma while improving the quality of life for myeloma patients in Israel, certainly can be proud of this additional achievement.


 related articles